Summary
The purpose of this study was to evaluate the efficacy and safety of selenium supplementation in patients with peripartum cardiomyopathy, a rare, life-threatening heart disease. One hundred subjects with a left ventricular ejection fraction of less than 45% (percentage of blood volume ejected from a ventricle during a cardiac action) and selenium deficiency took 200 µg of selenium daily for 3 months. The results showed a significant reduction in heart failure symptoms. For more details, see the study.
References
Karaye et al.